Exact Mass: 373.2205
Exact Mass Matches: 373.2205
Found 500 metabolites which its exact mass value is equals to given mass value 373.2205
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Curvacin A
Production by Lactobacillus curvatus LTH 1174. Bacteriocin.
Endoxifen
Endoxifen (EDX) is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptors that also inhibits aromatase activity. (PMID: 23274567) Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia) The pharmacological activity of Tamoxifen is dependent on its conversion to its active metabolite, endoxifen, by CYP2D6. (PMID: 23711794) Tamoxifen is a largely inactive pro-drug, requiring metabolism into its most important metabolite endoxifen. Since the cytochrome P450 (CYP) 2D6 enzyme is primarily involved in this metabolism, genetic polymorphisms of this enzyme, but also drug-induced CYP2D6 inhibition can result in considerably reduced endoxifen formation and as a consequence may affect the efficacy of tamoxifen treatment. (PMID: 23760858)
alpha-Hydroxy-N-desmethyltamoxifen
alpha-Hydroxy-N-desmethyltamoxifen is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
Spirotetramat
D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9268; ORIGINAL_PRECURSOR_SCAN_NO 9267 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9334; ORIGINAL_PRECURSOR_SCAN_NO 9333 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9232; ORIGINAL_PRECURSOR_SCAN_NO 9231 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9326; ORIGINAL_PRECURSOR_SCAN_NO 9325 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9276; ORIGINAL_PRECURSOR_SCAN_NO 9275 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9319; ORIGINAL_PRECURSOR_SCAN_NO 9318
N-Jasmonoyltyrosine
N-Jasmonoyltyrosine is found in pulses. N-Jasmonoyltyrosine is a constituent of the flowers of Vicia faba. Constituent of the flowers of Vicia faba. N-Jasmonoyltyrosine is found in pulses.
Dodecanedioylcarnitine
Dodecanedioylcarnitine is classified as a tricarboxylic acid or a Tricarboxylic acid derivative. Tricarboxylic acids are carboxylic acids containing exactly three carboxyl groups. Dodecanedioylcarnitine is considered to be a practically insoluble (in water) and a weak acidic compound. Dodecanedioylcarnitine can be found in blood. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
alpha-Hydroxy-N-desmethyl-tamoxifen
alpha-Hydroxy-N-desmethyl-tamoxifen is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
O-(11-Carboxyundecanoyl)carnitine
O-(11-Carboxyundecanoyl)carnitine is an acylcarnitine. More specifically, it is an dodecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-(11-Carboxyundecanoyl)carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine O-(11-Carboxyundecanoyl)carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2,3-Dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol
2-Hydroxy-3-methoxy-6beta-naltrexol
1-(3,5-Dimethyl-1-phenyl-4-pyrazolyl)-N-[4-(phenylmethyl)-1-piperazinyl]methanimine
Bunazosin
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine
(2s,5s)-2-Methyl-5-(4-(5-methyl-2-(p-tolyl)oxazol-4-yl)butyl)-1,3-dioxane-2-carboxylic acid
Ritobegron
Equisetin
A member of the class of tetramic acids that is trichosetin in which the hydrogen attached to the lactam nitrogen has been replaced by a methyl group. It is produced by the filamentous fungus Fusarium heterosporum.
(6alpha,7alpha)-6-hydroxy-21-(2-hydroxyethyl)-4-methyl-7,20-epoxyatid-16-en-19-one|spiramilactam A
pyrrole-2-carboxylic acid 13-hydroxy-11-oxo-dodecahydro-7,14-methano-dipyrido[1,2-a;1,2-e][1,5]diazocin-2-yl ester
6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-3,4-dihydro-1H-isoquinoline
2,3-methanediyldioxy-4,6beta-dimethoxy-17-methyl-10a-homo-morphin-8(14)-en-7beta-ol|Alkaloid CC-2|alkaloid CC-2 (Colchicum cornigerum)
(+)-4beta-N-methenetauryl-10beta-methoxy-1beta,5alpha,6beta,7beta-aromadendrane
ent-4,5alpha-epoxy-2,3,6beta-trimethoxy-17-methyl-10a-homo-morphin-8(14)-en-7beta-ol|Kreysiginin|Kreysiginine
3-oxo-11alpha,19,22-trihydroxycona-1,4-diene|pubatriol
C22H31NO4_(5R)-3-({(1S,2R,4aS,6R,8aR)-1,6-Dimethyl-2-[(1E)-1-propen-1-yl]-1,2,4a,5,6,7,8,8a-octahydro-1-naphthalenyl}carbonyl)-4-hydroxy-5-(hydroxymethyl)-1-methyl-1,5-dihydro-2H-pyrrol-2-one
Volinanserin
CONFIDENCE standard compound; INTERNAL_ID 893; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7066; ORIGINAL_PRECURSOR_SCAN_NO 7062 D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist CONFIDENCE standard compound; INTERNAL_ID 893; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7133; ORIGINAL_PRECURSOR_SCAN_NO 7131 CONFIDENCE standard compound; INTERNAL_ID 893; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7168; ORIGINAL_PRECURSOR_SCAN_NO 7167 CONFIDENCE standard compound; INTERNAL_ID 893; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7181; ORIGINAL_PRECURSOR_SCAN_NO 7180 CONFIDENCE standard compound; INTERNAL_ID 893; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7111; ORIGINAL_PRECURSOR_SCAN_NO 7109 CONFIDENCE standard compound; INTERNAL_ID 893; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7184; ORIGINAL_PRECURSOR_SCAN_NO 7181 Volinanserin is a potent and selective antagonist of 5-HT2 receptor, with a Ki of 0.36 nM, and shows 300-fold selectivity for 5-HT2 receptor over 5-HT1c, alpha-1 and DA D2 receptors. Volinanserin has antipsychotic activity.
Ala Ala Gly Arg
Ala Ala Asn Val
Ala Ala Arg Gly
Ala Ala Val Asn
Ala Gly Ala Arg
Ala Gly Ile Asn
Ala Gly Lys Val
Ala Gly Leu Asn
Ala Gly Asn Ile
Ala Gly Asn Leu
Ala Gly Gln Val
Ala Gly Arg Ala
Ala Gly Val Lys
Ala Gly Val Gln
Ala Ile Gly Asn
Ala Ile Asn Gly
Ala Lys Gly Val
Ala Lys Val Gly
Ala Leu Gly Asn
Ala Leu Asn Gly
Ala Asn Ala Val
Ala Asn Gly Ile
Ala Asn Gly Leu
Ala Asn Ile Gly
Ala Asn Leu Gly
Ala Asn Val Ala
Ala Gln Gly Val
Ala Gln Val Gly
Ala Arg Ala Gly
Ala Arg Gly Ala
Ala Val Ala Asn
Ala Val Gly Lys
Ala Val Gly Gln
Ala Val Lys Gly
Ala Val Asn Ala
Ala Val Gln Gly
Bunazosin
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Gly Ala Ala Arg
Gly Ala Ile Asn
Gly Ala Lys Val
Gly Ala Leu Asn
Gly Ala Asn Ile
Gly Ala Asn Leu
Gly Ala Gln Val
Gly Ala Arg Ala
Gly Ala Val Lys
Gly Ala Val Gln
Gly Gly Ile Lys
Gly Gly Ile Gln
Gly Gly Lys Ile
Gly Gly Lys Leu
Gly Gly Leu Lys
Gly Gly Leu Gln
Gly Gly Gln Ile
Gly Gly Gln Leu
Gly Ile Ala Asn
Gly Ile Gly Lys
Gly Ile Gly Gln
Gly Ile Lys Gly
Gly Ile Asn Ala
Gly Ile Gln Gly
Gly Lys Ala Val
Gly Lys Gly Ile
Gly Lys Gly Leu
Gly Lys Ile Gly
Gly Lys Leu Gly
Gly Lys Val Ala
Gly Leu Ala Asn
Gly Leu Gly Lys
Gly Leu Gly Gln
Gly Leu Lys Gly
Gly Leu Asn Ala
Gly Leu Gln Gly
Gly Asn Ala Ile
Gly Asn Ala Leu
Gly Asn Ile Ala
Gly Asn Leu Ala
Gly Gln Ala Val
Gly Gln Gly Ile
Gly Gln Gly Leu
Gly Gln Ile Gly
Gly Gln Leu Gly
Gly Gln Val Ala
Gly Arg Ala Ala
Gly Val Ala Lys
Gly Val Ala Gln
Gly Val Lys Ala
Gly Val Gln Ala
Ile Ala Gly Asn
Ile Ala Asn Gly
Ile Gly Ala Asn
Ile Gly Gly Lys
Ile Gly Gly Gln
Ile Gly Lys Gly
Ile Gly Asn Ala
Ile Gly Gln Gly
Ile Lys Gly Gly
Ile Asn Ala Gly
Ile Asn Gly Ala
Ile Gln Gly Gly
Lys Ala Gly Val
Lys Ala Val Gly
Lys Gly Ala Val
Lys Gly Gly Ile
Lys Gly Gly Leu
Lys Gly Ile Gly
Lys Gly Val Ala
Lys Ile Gly Gly
Lys Val Ala Gly
Lys Val Gly Ala
Leu Ala Gly Asn
Leu Ala Asn Gly
Leu Gly Ala Asn
Leu Gly Gly Lys
Leu Gly Gly Gln
Leu Gly Lys Gly
Leu Gly Asn Ala
Leu Gly Gln Gly
Leu Lys Gly Gly
Leu Asn Ala Gly
Leu Asn Gly Ala
Leu Gln Gly Gly
Asn Ala Ala Val
Asn Ala Gly Ile
Asn Ala Gly Leu
Asn Ala Ile Gly
Asn Ala Leu Gly
Asn Ala Val Ala
Asn Gly Ala Ile
Asn Gly Ala Leu
Asn Gly Ile Ala
Asn Gly Leu Ala
Asn Ile Ala Gly
Asn Ile Gly Ala
Asn Leu Ala Gly
Asn Leu Gly Ala
Asn Val Ala Ala
Gln Ala Gly Val
Gln Ala Val Gly
Gln Gly Ala Val
Gln Gly Gly Ile
Gln Gly Gly Leu
Gln Gly Ile Gly
Gln Gly Leu Gly
Gln Gly Val Ala
Gln Ile Gly Gly
Gln Leu Gly Gly
Gln Val Ala Gly
Gln Val Gly Ala
Arg Ala Ala Gly
Arg Ala Gly Ala
Arg Gly Ala Ala
Val Ala Ala Asn
Val Ala Gly Lys
Val Ala Gly Gln
Val Ala Lys Gly
Val Ala Asn Ala
Val Ala Gln Gly
Val Gly Ala Lys
Val Gly Ala Gln
Val Gly Lys Ala
Val Gly Gln Ala
Val Lys Ala Gly
Val Lys Gly Ala
Val Asn Ala Ala
Val Gln Ala Gly
Val Gln Gly Ala
N-Jasmonoyltyrosine
2-FLUORO-4-[[4-(TRANS-4-PENTYLCYCLOHEXYL)PHENYL]ETHYNYL]CYANOPHENYL
Urea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-(3-cyanophenyl)-N-cyclopentyl- (9CI)
3-N-BOC-AMINO-1-[2-AMINO-1-(4-TRIFLUOROMETHYL-PHENYL)-ETHYL]-PYRROLIDINE
Urea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-(4-cyanophenyl)-N-cyclopentyl- (9CI)
Urea, N-[2-[(3-cyano-6,8-dimethyl-2-quinolinyl)amino]ethyl]-N-(phenylmethyl)- (9CI)
N-tert-Butyl-O-[1-[4-(chloromethyl)phenyl]ethyl]-N-(2-Methyl-1-phenylpropyl)hydroxylamine
(3-BOC-AMINO-AZETIDIN-1-YL)-NAPHTHALEN-2-YL-ACETICACID
1-BOC-4-[CARBOXY-(1H-INDOL-2-YL)-METHYL]-[1,4]DIAZEPANE
5-ISOPROPYL-1-(2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOXY)ETHYL)-1H-1,2,3-TRIAZOL-4-OL
tert-Butyl (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutyl)carbamate
tert-Butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate
tert-butyl 4-[2-amino-1-[4-(trifluoromethyl)phenyl]ethyl]piperazine-1-carboxylate
1H-Benzimidazole,2-[1-[[1-(phenylmethyl)-1H-tetrazol-5-yl]methyl]-4-piperidinyl]-(9CI)
tert-Butyl 2-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetate
tert-Butyl 7-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate
tert-Butyl 6-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate
disodium N-(2-carboxyethyl)-N-dodecyl-beta-alaninate
5-(3-((1-amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl)-1H-indol-1-yl)pentanoicacid
2-[4-(1,2-diphenylbutyl)phenoxy]-N,N-dimethylethanamine
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
N-{(3s,4s)-4-[(6-Amino-4-Methylpyridin-2-Yl)methyl]pyrrolidin-3-Yl}-N-(4-Chlorobenzyl)ethane-1,2-Diamine
N-{(3r,4s)-4-[(6-Amino-4-Methylpyridin-2-Yl)methyl]pyrrolidin-3-Yl}-N-(3-Chlorobenzyl)ethane-1,2-Diamine
4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine
(4R)-4-[(1Z,5E,7E,11S)-11-methoxy-8-methyltetradeca-1,5,7,13-tetraenyl]-2-[(1R,2S)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole
N-[(2-hydroxy-1-naphthalenyl)-(4-methylphenyl)methyl]cyclohexanecarboxamide
O-dodecanedioylcarnitine
An O-acylcarnitine having 11-carboxyundecanoyl as the acyl substituent.
8-oxoresolvin D1(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 8-oxoresolvin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
17-oxoresolvin D1(1-)
A polyunsaturated fatty acid that is the conjugate base of 17-oxoresolvin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-[(1-Tert-butyl-5-tetrazolyl)-thiophen-2-ylmethyl]-2-azaspiro[5.5]undecane
(2S)-2-[[(2S)-4-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic acid
(2S,3R)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-2-(piperidine-1-carbonyl)-1-propanoyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
(2R,3S)-8-(1-cyclohexenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S,3aR,9bR)-1-(cyclohexylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
1-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-3-cyclopentyl-1-ethylurea
(2R,3R,3aS,9bS)-1-(cyclohexylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
1-[[(2S,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-3-cyclopentyl-1-ethylurea
1-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-3-cyclopentyl-1-ethylurea
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
13-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotridecanoate
(12R)-12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotridecanoate
(3Z,5R)-3-[[(1S,2R,4aS,6R,8aR)-1,6-dimethyl-2-[(E)-prop-1-enyl]-4a,5,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]-hydroxymethylidene]-5-(hydroxymethyl)-1-methylpyrrolidine-2,4-dione
(1S,7R,8S,13R,16S)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-oxido-11-azoniahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecan-4-one
(1S,7R,8S,13R,16S,17R)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-oxido-11-azoniahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecan-4-one
2-[[2-[(4-Amino-4-carboxybutanoyl)amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
2-Cyclohexyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1,2,3,4-tetrahydro-gamma-carboline
(1S,2R,7R,8S,13R,16S,17R)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-oxido-11-azoniahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecan-4-one
(2S)-N-(5-aminopentyl)-2-[[2-(1H-indol-3-yl)acetyl]amino]butanediamide
O-(11-carboxyundecanoyl)carnitine
An O-acylcarnitine having 11-carboxyundecanoyl as the acyl substituent.
7-oxoresolvin D2(1-)
A docosanoid anion that is the conjugate base of 7-oxoresolvin D2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
16-oxoresolvin D2(1-)
A docosanoid anion that is the conjugate base of 16-oxoresolvin D2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
O-dodecadienoyl-L-carnitine
An O-acyl-L-carnitine that is L-carnitine having a dodecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.